167 related articles for article (PubMed ID: 22989279)
21. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
[TBL] [Abstract][Full Text] [Related]
22. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India.
Ghosh A; Shaktan A; Basu D; Bn S; Naik SS; Mattoo SK
J Psychoactive Drugs; 2024; 56(3):364-372. PubMed ID: 37318513
[TBL] [Abstract][Full Text] [Related]
25. Predictors of outcome after short-term stabilization with buprenorphine.
Hillhouse M; Canamar CP; Ling W
J Subst Abuse Treat; 2013 Mar; 44(3):336-42. PubMed ID: 23021099
[TBL] [Abstract][Full Text] [Related]
26. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
[TBL] [Abstract][Full Text] [Related]
27. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
28. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
29. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
[TBL] [Abstract][Full Text] [Related]
30. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
Sigmon SC; Bigelow GE
Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
[No Abstract] [Full Text] [Related]
31. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
32. Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.
Monico LB; Mitchell SG; Gryczynski J; Schwartz RP; O'Grady KE; Olsen YK; Jaffe JH
J Subst Abuse Treat; 2015 Oct; 57():57-62. PubMed ID: 25980599
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine Provision by Early Career Family Physicians.
Tong ST; Hochheimer CJ; Peterson LE; Krist AH
Ann Fam Med; 2018 Sep; 16(5):443-446. PubMed ID: 30201642
[TBL] [Abstract][Full Text] [Related]
34. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
36. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
[TBL] [Abstract][Full Text] [Related]
37. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
[TBL] [Abstract][Full Text] [Related]
38. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
[TBL] [Abstract][Full Text] [Related]
39. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
Chou R; Ballantyne J; Lembke A
Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
[No Abstract] [Full Text] [Related]
40. Maintenance medication for opiate addiction: the foundation of recovery.
Bart G
J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
